Global Respiratory Disease Vaccine Market Size & Outlook
Global respiratory disease vaccine market, 2018-2030 (US$M)
Related Markets
Global respiratory disease vaccine market highlights
- The global respiratory disease vaccine market generated a revenue of USD 64,635.3 million in 2023 and is expected to reach USD 70,302.4 million by 2030.
- The market is expected to grow at a CAGR (2024 - 2030) of 1.2% by 2030.
- In terms of segment, viral vaccine accounted for a revenue of USD 35,445.3 million in 2023.
- Bacterial Vaccine is the most lucrative type segment registering the fastest growth during the forecast period.
- In terms of region, Asia Pacific was the largest revenue generating market in 2023.
- Country-wise, Japan is expected to register the highest CAGR from 2024 to 2030.
Global data book summary
| Market revenue in 2023 | USD 64,635.3 million |
| Market revenue in 2030 | USD 70,302.4 million |
| Growth rate | 1.2% (CAGR from 2023 to 2030) |
| Largest segment | Viral vaccine |
| Fastest growing segment | Bacterial Vaccine |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Viral Vaccine, Bacterial Vaccine, Combination Vaccine |
Other key industry trends
- In terms of revenue, the North America accounted for 28.4% of the global respiratory disease vaccine market in 2023.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, Japan is the fastest growing regional market and is projected to reach USD 3,587.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Respiratory Disease Vaccine Market Scope
Respiratory Disease Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novavax Inc | View profile | 1992 | 700 Quince Orchard Road, Gaithersburg, MD, United States, 20878 | https://www.novavax.com |
| Inovio Pharmaceuticals Inc | View profile | 122 | 660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, United States, 19462 | https://www.inovio.com |
| Bavarian Nordic A/S | View profile | 1381 | Philip Heymans Alle 3, Hellerup, Denmark, DK-2900 | https://www.bavarian-nordic.com |
| Moderna Inc | View profile | 5600 | 200 Technology Square, Cambridge, MA, United States, 02139 | https://www.modernatx.com |
| Emergent BioSolutions Inc | View profile | 1600 | 300 Professional Drive, Gaithersburg, MD, United States, 20879 | https://www.emergentbiosolutions.com |
| Sinovac Biotech Ltd | View profile | 3261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | http://www.sinovac.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Serum Institute of India Pvt. Ltd. | View profile | 1001-5000 | Pune, Maharashtra, India, Asia | http://www.seruminstitute.com/ |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Johnson & Johnson | View profile | 134400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | https://www.jnj.com |
Global respiratory disease vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to respiratory disease vaccine market will help companies and investors design strategic landscapes.
Viral vaccine was the largest segment with a revenue share of 54.84% in 2024. Horizon Databook has segmented the Global respiratory disease vaccine market based on viral vaccine, bacterial vaccine, combination vaccine covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Respiratory Disease Vaccine Type Outlook (Revenue, USD Million, 2018-2030)
- Viral Vaccine
- Bacterial Vaccine
- Combination Vaccine
- Global Respiratory Disease Vaccine Age Group Outlook (Revenue, USD Million, 2018-2030)
- Pediatric
- Adult
- Global Respiratory Disease Vaccine Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Other Distribution Channels
- Government Suppliers
- Hospital & Retail Pharmacies
- Global Respiratory Disease Vaccine Infection Outlook (Revenue, USD Million, 2018-2030)
- COVID-19
- Influenza
- Respiratory Syncytial Virus (RSV)
- Pneumonia
- Other Infections
Reasons to subscribe to Global respiratory disease vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global respiratory disease vaccine market databook
-
Our clientele includes a mix of respiratory disease vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global respiratory disease vaccine market, including forecasts for subscribers. This global databook contains high-level insights into Global respiratory disease vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global respiratory disease vaccine market size, by regions, 2018-2030 (US$M)
Top 10 countries: Respiratory disease vaccine market size, 2024 (US$M)
Global respiratory disease vaccine market share, by age group, 2024 & 2030 (%, US$M)
Respiratory disease vaccine market: Opportunity assessment by country
Global respiratory disease vaccine market, by region, 2024 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
